Arcellx (ACLX) Research & Development (2021 - 2025)
Arcellx's quarterly Research & Development came in at $34.1 million in Q4 2025, down 23.64% year-on-year from $44.6 million in Q4 2024, and down 2.83% quarter-over-quarter from $35.1 million in Q3 2025.
Arcellx has reported Research & Development for 5 years, with the latest figure at $34.1 million in Q4 2025.
- For the quarter ending Q4 2025, Research & Development fell 23.64% year-over-year to $34.1 million; the trailing twelve-month figure through Dec 2025 stood at $157.6 million (changed 0.33% YoY), and the FY2025 full-year result was $157.6 million, changed 0.33% from the prior year.
- Research & Development for Q4 2025 stood at $34.1 million, down from $35.1 million in the prior quarter.
- The five-year high for Research & Development was $83.5 million in Q3 2022, with the low at $8.5 million in Q1 2021.
- Average Research & Development over 5 years is $32.2 million, with a median of $32.6 million recorded in 2023.
- Year-over-year, Research & Development surged 577.27% in 2022 and slumped 47.52% in 2023.
- Tracing ACLX's Research & Development over 5 years: stood at $13.4 million in 2021, then surged by 93.69% to $25.9 million in 2022, then grew by 10.95% to $28.8 million in 2023, then jumped by 55.12% to $44.6 million in 2024, then slipped by 23.64% to $34.1 million in 2025.
- The last three Research & Development figures came in at $34.1 million (Q4 2025), $35.1 million (Q3 2025), and $37.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 34.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34.10 Mn |
| Sep 30, 2025 | 35.09 Mn |
| Jun 30, 2025 | 37.63 Mn |
| Mar 31, 2025 | 50.80 Mn |
| Dec 31, 2024 | 44.65 Mn |
| Sep 30, 2024 | 39.17 Mn |
| Jun 30, 2024 | 40.95 Mn |
| Mar 31, 2024 | 32.32 Mn |
| Dec 31, 2023 | 28.78 Mn |
| Sep 30, 2023 | 43.81 Mn |
| Jun 30, 2023 | 28.33 Mn |
| Mar 31, 2023 | 32.93 Mn |
| Dec 31, 2022 | 25.94 Mn |
| Sep 30, 2022 | 83.47 Mn |
| Jun 30, 2022 | 22.08 Mn |
| Mar 31, 2022 | 18.06 Mn |
| Dec 31, 2021 | 13.39 Mn |
| Sep 30, 2021 | 12.33 Mn |
| Jun 30, 2021 | 12.64 Mn |
| Mar 31, 2021 | 8.52 Mn |